bioRxivMicrobiologyPreprint
Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies
F. Ferrara, G. Carnell, R. Kinsley, E. Bottcher-Friebertshauser, S. Pohlmann, S. Scott, S. Fereidouni, D. Corti, P. Kellam, S. Gilbert, N. J. Temperton
Abstract
Influenza B viruses cause respiratory disease epidemics in human populations and are included in seasonal influenza vaccines. Serological methods are employed to evaluate vaccine immunogenicity prior to licensure. However, the haemagglutination inhibition assay, which represents the gold standard for assessing the immunogenicity of influenza vaccines, has been shown to be relatively insensitive for the detection of antibodies against influenza B viruses. Furthermore, this assay, and the serial radial haemolysis assay are not able to detect stalk-directed cross-reactive antibodies. For these reasons there is a need to develop new assays that can overcome these limitations. The use of replication-defective viruses, such as lentiviral vectors pseudotyped with influenza A haemagglutinins, in microneutralization assays is a safe and sensitive alternative to study antibody responses elicited by natural infection or vaccination. We have produced Influenza B haemagglutinin-pseudotypes using plasmid-directed transfection. To activate influenza B haemagglutinin, we have explored the use of proteases by adding relevant encoding plasmids to the transfection mixture. When tested for their ability to transduce target cells, the newly produced influenza B pseudotypes exhibit tropism for different cell lines. Subsequently the pseudotypes were evaluated as surrogate antigens in microneutralization assays using reference sera, monoclonal antibodies, human sera collected during a vaccine immunogenicity study and surveillance sera from seals. The influenza B pseudotype virus neutralization assay was found to effectively detect neutralizing and cross-reactive responses despite lack of significant correlation with the haemagglutinin inhibition assay.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=61 SRC=\"FIGDIR/small/492785_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (19K):\norg.highwire.dtl.DTLVardef@d5d8e7org.highwire.dtl.DTLVardef@1934a06org.highwire.dtl.DTLVardef@e0d0b8org.highwire.dtl.DTLVardef@1a717e0_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- organism: multiple species
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Influenza A (N1-N9) and Influenza B (B/Vic and B/Yam) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine design
K. A. S. da Costa, J. M. M. Del Rosario, … N. J. Temperton·bioRxiv·Sep 19, 2021
- Establishment of pan-Influenza A (H1-H18) and pan-Influenza B (pre-split, Vic/Yam) Pseudotype Libraries for efficient vaccine antigen selection
J. M. Del Rosario, K. da Costa, … N. J. Temperton·bioRxiv·May 20, 2021
- The study of antibody responses to influenza neuraminidase using a lentiviral pseudotype based ELLA
Fabrizio Biuso, George Carnell, … Nigel Temperton·bioRxiv·Nov 13, 2017
- A rapid and flexible microneutralization assay for serological assessment of influenza viruses
K. E. Rumfelt, W. J. Fitzsimmons, … A. S. Lauring·bioRxiv·Feb 2, 2023
- Development and optimisation of Influenza C and Influenza D pseudotyped viruses
Maria Marotta, Martin Mayora Neto, … Nigel James Temperton·Journal of Virological MethodsPeer-reviewed·Aug 23, 2025
- The use of hyperimmune chicken reference sera is not appropriate for the validation of influenza pseudotype neutralization assays
F. Ferrara, E. Molesti, … N. J. Temperton·bioRxiv·Aug 23, 2017